James Mwangi's Equity Group opens its first pharmacy in a push for cheaper medicine in Kenya

Equity Group Holdings has opened its first pharmacy outlet in Kenya, extending the financial conglomerate's reach deeper into healthcare as it works to bring down the cost of medicine for its insurance customers and the wider public.

Group chief executive James Mwangi confirmed the move at a briefing in Nairobi, framing it as the next stage of a vertically integrated healthcare strategy built around Equity Afia, the network of outpatient clinics the bank has operated for years. "We are piloting our first pharmacy, the Equity Afia Pharmacy, so that we not only make access to doctors affordable and accessible, but we ensure pharmaceutical commodities are affordable," Mwangi said.

The pharmacy push comes as a growing number of insurers in Kenya establish in-house dispensing operations to control the cost of pharmaceutical claims. CIC Insurance Group operates CIC Pharmacy Limited, while AAR Insurance runs AAR Healthcare Limited. Equity's entry follows the same logic: claims data across the industry consistently shows that pharmaceutical costs and outpatient care together represent the largest controllable share of health insurance payouts.

Angela Okinda, an insurance executive at Equity, said the group's existing Equity Afia network already gives it a meaningful cost advantage over rival providers. "One of the things that gives us an advantage is the partnership with Equity Afia," she said. "With Equity Afia, outpatient costs usually are between Sh8,000 and Sh10,000 and, for a health cover, outpatient on its own is 50 to 60 percent of the cost, so it's a big driver. Equity Afia at the moment is delivering full outpatient care at 40 percent lower than the other providers."

Equity Afia operates 146 outlets across Kenya and a further four in the Democratic Republic of Congo. Equity staff are required to use Equity Afia facilities as the first point of care before being referred elsewhere if a case needs to be escalated, a policy designed to keep routine costs inside the group's own network rather than leaking out to more expensive providers.

The timing of the pharmacy launch is deliberate. Patents on a wide range of medicines are expiring, opening the door to cheaper generic alternatives, while Kenya's healthcare sector continues to grapple with high drug prices and the persistent infiltration of counterfeit medicines into the retail supply chain. By operating its own pharmacy, Equity gains direct control over sourcing, pricing and quality assurance for the medicines its insurance customers ultimately consume.

The move sits inside a broader pattern Mwangi has described publicly: Equity Group's evolution from a pure banking institution into a diversified financial services group spanning banking, insurance, asset management and now pharmaceutical retail. Equity Insurance Group reported a 30 percent increase in gross written premiums to KES 4.5 billion in the first quarter of 2026, with profit before tax up 53 percent to KES 640 million, growth rates significantly ahead of the group's core banking business and a sign of how much room remains for expansion in a market where insurance penetration is still comparatively low.

Mwangi, who has led Equity Group since 2004 and built it from a Kenyan community lender into a pan-African financial institution with 22.7 million customers across seven markets, holds 127.8 million shares in the group, a stake worth approximately $75 million at current prices. The pharmacy pilot is a small initial step relative to the scale of Equity's banking and insurance operations, but it reflects the same underlying instinct that has defined his three-decade tenure: identify a cost or access gap affecting ordinary customers, and build the infrastructure to close it directly rather than wait for the market to do so.